Inflammatory cytokine pathways - indirect modulation

Inflammatory cytokine pathways - indirect modulation refers to a therapeutic strategy that regulates the immune system by targeting the intracellular machinery responsible for cytokine production and signaling, rather than the cytokines themselves. This approach typically involves the use of small molecules to inhibit enzymes like Janus kinases (JAKs) or phosphodiesterases, or to activate nuclear receptors that repress inflammatory gene expression (Nature Reviews Immunology, 2013). By influencing these central nodes, drugs can simultaneously dampen the effects of multiple pro-inflammatory mediators, such as TNF-alpha, IL-6, and IL-17, which are critical in the pathogenesis of chronic inflammatory diseases (Frontiers in Immunology, 2021). This broad-spectrum activity makes indirect modulation highly effective for conditions like rheumatoid arthritis and psoriasis where multiple pathways are dysregulated. However, because these signaling pathways are also involved in normal immune surveillance and cellular homeostasis, indirect modulation carries risks of systemic side effects, including increased susceptibility to infections and laboratory abnormalities (Journal of Clinical Investigation, 2019). Consequently, while powerful, this strategy requires careful patient monitoring and dose optimization to balance efficacy with safety.

Other names

Indirect cytokine inhibitionCytokine signaling pathway modulationUpstream inflammatory regulationIntracellular cytokine signaling modulation

Indirect modulation involves the inhibition of intracellular signaling molecules, such as Janus kinases (JAKs) or phosphodiesterase 4 (PDE4), or the activation of nuclear receptors like the glucocorticoid receptor to suppress the transcription and release of multiple pro-inflammatory cytokines (Nature Reviews Drug Discovery, 2017; British Journal of Pharmacology, 2011).